Resmetirom

Resmetirom has been studied in 41 papers since 2024: 1 trial and 1 observational study in people, 2 in animals, 1 in cells, 34 reviews; 33 in the past year. It is an approved medicine. The newest paper, Nov 16, 2026: “Real‐World Initiation of Resmetirom and Recorded Incretin Exposure in the United States”.

InterventionApproved 2024

41 papers study it11 more mention it25 findingsUpdated

PubChemMeSH

12 new papers in 30 daysSee all 51 papers on resmetirom

At a glance

Independent labs found the same change in people. 6 independent labs in 5 countries; 14 trials, none about aging, 3 with no results posted.

“Low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and lipoprotein(a) [Lp(a)] were reduced irrespective of baseline statin use;”
Potential for cardiovascular benefits of resmetirom based on LDL-cholesterol and lipoprotein(a) lowering consistent across statin subgroups, a secondary analysis of the MAESTRO-NASH phase 3 clinical trialJournal of clinical lipidology2026doi:10.1016/j.jacl.2026.10.004

1 of its findings points the other way.

Humans: replicated by independent labs. Cells and mice: a single group. Worms or flies: nothing yet.
  • 6 independent labs in 5 countries
  • 1 finding against
  • 14 trials, none about aging, 3 with no results posted
  • Funders: Madrigal Pharmaceuticals and others
  • 5 of 17 findings with company ties
  • 12 of 14 trials sponsored by its developers
  • Human trial1
  • Humans1
  • Animals2
  • Cells1
  • In silico2

What did studies of resmetirom find?

21

Studies of resmetirom measured 21 outcomes, among them liver fibrosis, LDL cholesterol and liver fibrosis.

Liver fibrosis

downin humans2no changein humans1RR 1.37–1.99

2 studies
  1. Resmetirom decreases liver fibrosis in humans (regardless of baseline statin use).

    Human trialregardless of baseline statin useliver52 weeks

  2. Resmetirom showed no clear effect on liver fibrosis in MASH patients without T2DM (RR = 1.37, 95% CI 0.83-2.25, p = 0.21).

    Reviewin MASH patients without T2DM52-72 weeksn = 319

  3. Resmetirom decreases liver fibrosis in MASH patients with T2DM (RR = 1.99, 95% CI 1.35-2.93, p = 0.0005).

    Reviewin MASH patients with T2DM52-72 weeksn = 647

LDL cholesterol

downin humans2

2 studies
  1. Resmetirom decreases LDL cholesterol in humans with or without baseline statin use; placebo-corrected changes (80 mg and 100 mg, respectively: −12.0% and −18.7% on statins; −15.3% and −14.1% not on statins).

    Human trialwith or without baseline statin use; placebo-corrected changes80 mg or 100 mg24 weeks

  2. Resmetirom decreases LDL cholesterol in humans (-15.21% LDL cholesterol (95% CI -18.99 to -11.43)).

    Reviewn = 1,996

More on LDL cholesterol

Liver fibrosis

downin humans1downin reviews1

2 studies
  1. Resmetirom decreases liver fibrosis in humans.

    Reviewliver52 weeks

  2. Resmetirom decreases liver fibrosis.

    Reviewin adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2), if locally approvedliver

More on Liver fibrosis

Projected 10-year atherosclerotic cardiovascular disease risk

downin humans1

1 study
  1. Resmetirom decreases projected 10-year atherosclerotic cardiovascular disease risk in humans (Modeled using epidemiological frameworks, not observed clinical events) (Projected relative risk reductions: 2.3% Lp(a) model, 19.3% apoB model, 9.8% LDL-cholesterol model, and 11.8% combined model).

    ReviewModeled using epidemiological frameworks, not observed clinical events10 years (modeled projection)

Systolic blood pressure

downin humans1

1 study
  1. Resmetirom decreases systolic blood pressure in humans (-3.08 mmHg systolic and -1.74 mmHg diastolic blood pressure).

    Review

Hepatic and metabolic outcomes

upin humans1

1 study
  1. Resmetirom improves hepatic and metabolic outcomes in humans (metabolic dysfunction-associated steatotic liver disease and obesity).

    Reviewmetabolic dysfunction-associated steatotic liver disease and obesityliver

Statin-related adverse events

no changein humans1

1 study
  1. Resmetirom showed no clear effect on statin-related adverse events in humans (baseline statin use).

    Human trialbaseline statin use52 weeks

Liver fat

downin humans1

1 study
  1. Resmetirom decreases liver fat in humans (regardless of baseline statin use).

    Human trialregardless of baseline statin useliver52 weeks

MASH resolution

upin humans1

1 study
  1. Resmetirom increases MASH resolution in humans (regardless of baseline statin use).

    Human trialregardless of baseline statin useliver52 weeks

Autophagy

upin mouse cells1

1 study
  1. Resmetirom activates autophagy in AML12 cells.

    Cellsin AML12 cells

    Aging and Western diet impair thyroid hormone signaling in mice

    Aging cell

More on Autophagy

All 21

Has resmetirom been tested in people?

0 of 14 about aging

Yes: 1 trial and 1 observational study in people have been published, and 11 trials are registered.

Approved

  • FDA Rezdiffra

    Mar 14, 2024metabolic dysfunction-associated steatohepatitis, steatohepatitis, nonalcoholic steatohepatitis

  • EMA Rezdiffra

    Aug 18, 2025Non-alcoholic Fatty Liver Disease, metabolic dysfunction-associated steatohepatitis

Repurposing

All 7

In trials

  • MASH metabolic dysfunction associated steatohepatitis

    Phase 4Recruiting3 trials

  • Hyperlipidemias

    Phase 3Completed2 trials

  • Thyroid Hormone Resistance Syndrome

    Phase 3Completed2 trials

  • Drug safety

    Phase 1Completed1 trial

Who is developing resmetirom?

2 companies: Madrigal Pharmaceuticals and Sagimet Biosciences.

Companies
  • Madrigal PharmaceuticalsPhase 4mash metabolic dysfunction associated steatohepatitis, non-alcoholic fatty liver disease
  • Sagimet BiosciencesPhase 1

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 6Feb 2026: 4Mar 2026: 4Apr 2026: 1May 2026: 0Jun 2026: 3Jul 2026: 1Aug 2026: 3Sep 2026: 6Oct 2026: 7Nov 2026: 440 papers in 12 months

See all 51 papers on resmetirom